ROBO Global Healthcare Tech and Innovation ETF

Amundi Reduced Holdings in Intuitive Surgical

Guardant Health insiders sold $5.846 million worth of shares

Guardant Health Exec Monroe Terilyn J Sells $5.8M in Shares

Natera Inc. CEO Disposes of Common Stock

Natera's Clinical Diagnostics President Reports Sale of Ordinary Shares

HC Wainwright Raises Arrowhead Pharmaceuticals' Target Price to $85

Sanofi and Regeneron Obtain EU Approval for Dupixent to Treat Chronic Urticaria

Natera Inc. showcases new data for Signatera™ at ASH annual meeting

Creative Planning and other investors increase holdings in GRAIL stock

Intuitive Surgical VP Myriam Curet Sells Shares

Intuitive Surgical's Chairman Gary S. Guthart Sold Company Shares

Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran

Natera to Present Signatera Detection Data at San Antonio Breast Cancer Symposium

Panagora Asset Management Inc. Significantly Increases Holdings in Intuitive Surgical

Arrowhead Pharmaceuticals Director Reports Sale of Company Common Stock

Arrowhead Pharmaceuticals to Participate in Multiple Medical Conferences in December 2025 and Present on RNAi Therapies

Arrowhead Pharmaceuticals to Attend Multiple Healthcare Conferences in December 2025 to Showcase Plozasiran Progress

New York State Common Retirement Fund Reduces Holdings in Regeneron Pharmaceuticals

Regeneron and Tessera Collaborate on Gene Editing Therapy

Loomis Sayles Reduces Stake in Natera, Stock Rises

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Tradr 2X Long ASTS Daily ETF

Able View Global

ISRG

Amundi reduced its stake in Intuitive Surgical by 24.7% in Q2, now holding 2,488,028 shares valued at $1.35 billion. Other institutional investors like Norges Bank and Vanguard Group have also adjusted their positions. Analysts have varied ratings on Intuitive Surgical, with a consensus price target of $607.17. Insider transactions include significant stock sales by executives. Intuitive Surgical's stock opened at $568.63, with a market cap of $203.84 billion.

Market Beat

Intuitive Surgical

Amundi Has $1.35 Billion Stock Position in Intuitive Surgical, Inc. $ISRG

Guardant Health, Inc.'s common stock is subject to a lock-up agreement ending on December 5, 2025. The lock-up period lasts 31 days, from November 4 to December 5, 2025. During this time, directors and executive officers cannot sell or transfer shares without consent from Goldman Sachs & Co. LLC and Jefferies LLC, with specified exceptions.

marketscreener

Guardant Health

Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.

ADPT

Officer Robins Harlan S of Adaptive Biotechnologies Corp filed a Form 144 with the SEC to sell 10,000 shares on December 4, 2025, through Goldman Sachs & Co, under a prearranged trading plan (10b5-1).

Reuters

Adaptive Biotechnologies

Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT]

Guardant Health Insider Sold Shares Worth $5,846,163, According to a Recent SEC Filing

Guardant Health Insider Sold Shares Worth $5,846,163, According to a Recent SEC Filing

Monroe Terilyn J, an officer of Guardant Health Inc, sold 55,167 shares worth $5.8 million as disclosed in a Form 4 filed with the SEC on December 3, 2025. The sale was executed under a prearranged trading plan (10b5-1).

Officer Monroe Sells 55,167 ($5.8M) Of Guardant Health Inc [GH]

NTRA

Natera's CEO and President, Steven Leonard Chapman, and President of Clinical Diagnostics, Solomon Moshkevich, both sold shares of the company's common stock on December 1, 2025. Chapman sold 4,400 shares for $1,047,501, reducing his ownership to 140,416 shares. Moshkevich sold 3,000 shares for $714,458, reducing his ownership to 109,061 shares. Both transactions were executed under Rule 10b5-1 trading plans.

TradingView

Natera

Natera Executives Engage in Stock Sales

Moshkevich Solomon Officer of Natera Inc [NTRA] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/1/25TransactionPlanned Sale(1) Shares3,000Price$238.15Value$714,459Ending Holdings: 109,061 - Direct(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Moshkevich Sells 3,000 ($714.5K) Of Natera Inc [NTRA]

Solomon Moshkevich, President of Clinical Diagnostics at Natera Inc., reported the sale of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.

Natera President of Clinical Diagnostics Solomon Moshkevich Reports Sale of Common Shares

Natera Inc.'s CEO and President, Steven Leonard Chapman, has reported the disposal of common shares of the company. The details are available in the filing on EDGAR, the SEC's system. This announcement is informational and not financial advice.

Natera CEO and President Steven Leonard Chapman Reports Disposal of Common Shares

REGN

Shares of Regeneron Pharmaceuticals Inc. (REGN) fell 2.47% to $723.67 on Wednesday, marking the fifth consecutive day of losses. The stock underperformed compared to competitors like Amgen Inc., Moderna Inc., and Gilead Sciences Inc., which saw gains. Despite a strong overall market performance, Regeneron closed 9.65% below its 52-week high. Trading volume was 1.2 million, above the 50-day average of 1.1 million.

Dow Jones

Regeneron Pharma

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Regeneron Shares Fall After Morgan Stanley Downgrade

Regeneron Shares Fall After Morgan Stanley Downgrade

ARWR

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reached a new 52-week high after HC Wainwright raised its price target from $80 to $85, maintaining a buy rating. The stock traded as high as $59.27, closing at $58.53. Other analysts have also issued positive ratings, contributing to the stock's rise. Insiders sold shares recently, and institutional investors have been active in trading. Arrowhead Pharmaceuticals has a market cap of $7.93 billion and develops medicines for intractable diseases.

ArrowHead Pharma

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week High After Analyst Upgrade

SNYNF

Sanofi SA and Regeneron have received EU approval for Dupixent (dupilumab) to treat moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older. This marks the first targeted treatment approval for CSU in over a decade, based on positive phase 3 clinical trials. Dupixent is now approved in the EU, US, and Japan for this indication.

Sanofi

Sanofi and Regeneron win EU approval for Dupixent in chronic spontaneous urticaria

Natera Inc. will present new data on its Signatera™ test at the 2025 ASH Annual Meeting, highlighting its superior detection of lymphoma recurrence. Signatera outperformed standard methods, detected recurrence before imaging, and clarified ambiguous imaging results. It also serves as a response assessment tool, with ctDNA-measurable residual disease included in NCCN Guidelines for diffuse large B-cell lymphoma. The findings will be shared in oral and poster sessions.

Natera Unveils New Signatera Data Showing Superior Lymphoma Recurrence Detection at ASH 2025

GRAL

Creative Planning purchased a new stake in GRAIL, Inc. (NASDAQ:GRAL) worth $725,000 in the second quarter. Other investors, including Police & Firemen's Retirement System of New Jersey and Geode Capital Management, also increased their positions. GRAIL's stock performance has been strong, with a recent price of $97.38. The company reported better-than-expected earnings and has received mixed ratings from analysts. Insiders have sold shares recently, and the company targets the $100B cancer market.

GRAIL

Creative Planning Takes $725,000 Position in GRAIL, Inc. $GRAL